← All news
Markets

Are Small-Cap Innovators on AIM Poised for Explosive Growth as Capital Rotates Away from Mega-Cap Tech?

1 source ·1 article ·Aug 7, 09:02 UTC AIM ImmunoTech

Highlights Early-stage technology companies receive minimal institutional research coverage, creating valuation inefficiencies where breakthrough innovations trade at distressed valuations Capital flowing away from mega-cap technology towar…

Covered by 1 outlet

All coverage · 1 article